Marinus Appoints Michael R. Dougherty to its Board of Directors
February 1, 2017Marinus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the appointment of Michael R. Dougherty to its Board of Directors.
More »
Esperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with Hypercholesterolemia
January 25, 2017Approximately 2,000 Patients Enrolled Ahead of Schedule Following Study Expansion in October 2016 Global Study Enrolled Patients with Hypercholesterolemia with ASCVD and/or HeFH at High CVD Risk Top-Line Results Expected by Q2 2018
More »
MARINUS ANNOUNCES POSITIVE PRELIMINARY DATA FROM CHILDREN WITH CDKL5 GENETIC DISORDER
January 23, 2017Plans to Apply for Orphan Drug Designation
More »